Skip to main content
Premium Trial:

Request an Annual Quote

Daiichi Licenses Inpharmatica s ADME Platform Admensa Interactive

NEW YORK, June 6 (GenomeWeb News) - Daiichi Pharmaceuticals has licensed Inpharmatica's Admensa Interactive, a suite of ADME models and compound prioritization tools, the companies said today.


Daiichi has also made a "significant" yet undisclosed milestone payment to Inpharmatica after the company identified a "novel" drug target using its Chematica services and virtual screening technology.


Inpharmatica said Daiichi is the first Japanese company to license Admensa Interactive. In 2002, Daiichi obtained  a nonexclusive subscription to Inpharmatica's Biopendium protein database.


Chematica and Admensa Interactive are components of PharmaCarta, Inpharmatica's gene-to-candidate platform which integrates biology- and chemistry-based drug discovery activities.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.